A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland
Authors
- R Audran (ORCID: https://orcid.org/0000-0002-5071-8403)
- François Spertini (ORCID: https://orcid.org/0000-0002-3256-1377)
- Hélène Maby–El Hajjami (ORCID: https://orcid.org/0000-0002-5786-5991)
- Alix Miauton (ORCID: https://orcid.org/0000-0003-1849-8874)
- Mary‐Anne Hartley (ORCID: https://orcid.org/0000-0002-8826-3870)
- Vincent Faivre (ORCID: https://orcid.org/0000-0002-4103-7665)
- Mohamed Faouzi (ORCID: https://orcid.org/0000-0003-2084-3235)
- Loane Warpelin‐Decrausaz
- Blaise Genton (ORCID: https://orcid.org/0000-0002-5134-7683)
- Maxime Karlen
- Loredana Sene
- Sylvain Schaufelberger
- Juliette Besson
Institutions
- Centre Hospitalier Universitaire Vaudois (CH)
- Centre universitaire de médecine générale et santé publique, Lausanne (CH)
- University of Lausanne (CH)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1186/s12879-025-10844-3
- Citations
- 4
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 5.58
Funders
- Université de Lausanne
- Centre Hospitalier Universitaire Vaudois